MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ
28.03
-0.71
-2.47%
After Hours: 28.03 0 0.00% 16:05 05/14 EDT
OPEN
28.73
PREV CLOSE
28.74
HIGH
29.12
LOW
27.70
VOLUME
591.55K
TURNOVER
--
52 WEEK HIGH
62.58
52 WEEK LOW
23.42
MARKET CAP
1.62B
P/E (TTM)
2.484
1D
5D
1M
3M
1Y
5Y
1D
Agios to highlight PK activation portfolio with data in blood disorders at EHA
TipRanks · 6h ago
Agios Pharma: New Data On PK Activators, Mitapivat And Tebapivat, To Be Featured In Oral And Poster Presentations During EHA Congress 2025
Benzinga · 6h ago
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Barchart · 11h ago
Weekly Report: what happened at AGIO last week (0505-0509)?
Weekly Report · 2d ago
AGIOS PHARMACEUTICALS INC <AGIO.O>: JP MORGAN CUTS TARGET PRICE TO $38 FROM $43
Reuters · 05/07 12:06
Hold Rating for Agios Pharma Amid Regulatory Milestones and Financial Uncertainty
TipRanks · 05/06 06:05
Weekly Report: what happened at AGIO last week (0428-0502)?
Weekly Report · 05/05 09:03
Agios Pharmaceuticals Price Target Cut to $71.00/Share From $74.00 by Scotiabank
Dow Jones · 05/02 14:26
More
About AGIO
More
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Recently
Symbol
Price
%Change

Webull offers Agios Pharmaceuticals Inc stock information, including NASDAQ: AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.